Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The AadR-FixK hierarchy coordinates iron-responsive metabolism via Fur-family regulators in <i>Rhodopseudomonas palustris</i> TIE-1.

bioRxiv : the preprint server for biology·2026
Same author

Artificial Intelligence in single-cell and spatial transcriptomics data analyses.

Progress in molecular biology and translational science·2026
Same author

Correlation between liver stiffness measurement and hepatocellular carcinoma risk: A case control study.

Bioinformation·2026
Same author

Reply to Roepe, "The collective creativity of Drs. Baro, Pooput, and Callaghan".

Antimicrobial agents and chemotherapy·2026
Same author

Differential expression of mitochondria-associated genes in clinical samples of Plasmodium falciparum showing severe manifestations.

BMC genomics·2026
Same author

Temporal and weather-specific analysis of injury severity in three-wheeled rickshaw crashes: a heterogeneity-aware modeling approach.

International journal of injury control and safety promotion·2026

相关实验视频

Updated: Feb 28, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

分子对接和MD建模技术用于开发新型ROS1激酶抑制剂.

Mohammad Jahoor Alam1, Arshad Jamal1, Shaik Daria Hussain2

  • 1Department of Biology, College of Science, University of Ha'il, Ha'il 2440, Saudi Arabia.

Pharmaceuticals (Basel, Switzerland)
|February 27, 2026
PubMed
概括

这项研究确定了四种新型候选药物,它们有效对抗突变的ROS1,这是化学疗法耐药性的关键因素. 这些化合物显示出在癌症治疗中克服对酶抑制剂 (如crizotinib) 的耐药性的前景.

关键词:
模拟MD的模拟方法在MM-GBSA中使用.在ROS1上,它是ROS1的.克里佐丁尼布 (crizotinib) 的使用方法分子对接的分子对接.

更多相关视频

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.3K
Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

1.2K

相关实验视频

Last Updated: Feb 28, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.3K
Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

1.2K

科学领域:

  • 在瘤学瘤学.
  • 计算化学的计算化学
  • 药物发现 药物发现 药物发现

背景情况:

  • 化疗耐药性是癌症治疗的一个主要障碍.
  • 在ROS1 (受体氨酸激酶) 中的Gly2032Arg突变赋予了对crizotinib的耐药性.
  • 向突变的ROS1对于开发新的抗癌疗法至关重要.

研究的目的:

  • 为了确定针对Gly2032Arg突变的ROS1蛋白的新药候选者.
  • 通过计算来选对抗抗克里佐替尼抗性ROS1.1有效的分子.
  • 为具有ROS1突变的癌症提供新的治疗策略.

主要方法:

  • 在Gly2032Arg突变的ROS1蛋白的模拟中.
  • 基于结构的PubChem数据库的虚拟选.
  • 分子对接,MM-GBSA,分子动力学 (MD) 模拟和DFT计算.

主要成果:

  • 确定了四种有前途的候选药物 (PubChem CID: 67463531, 72544946, 139431449, 139431487),其对接分数高,与药物相似.
  • 通过MM-GBSA和MD模拟验证了蛋白质-配体复合物的结合亲和力和稳定性.
  • 使用DFT识别的化合物的解析分子特征.

结论:

  • 已识别的化合物显示出对突变的ROS1标的潜在有效性.
  • 这项研究为开发克服化疗耐药性的药物提供了新的途径.
  • 这些发现有助于开发向癌症治疗方法.